Core Viewpoint - The internal control evaluation report of Reap Bio Co., Ltd. indicates that there are no significant defects in both financial and non-financial reporting internal controls as of the evaluation date, affirming the effectiveness of the company's internal control system [2][14]. Internal Control Objectives - The objectives of the internal control system include ensuring legal compliance in management, safeguarding assets, ensuring the accuracy of financial reporting, improving operational efficiency, and supporting the achievement of strategic goals [2]. Internal Control Evaluation Conclusion - The board of directors confirms that there are no significant defects in financial reporting internal controls and non-financial reporting internal controls as of the evaluation date [2][14]. Internal Control Evaluation Scope - The evaluation covers the company and its wholly-owned and controlled subsidiaries, which account for 100% of total assets and total revenue in the consolidated financial statements [3]. High-Risk Areas - Key high-risk areas evaluated include procurement, sales, engineering activities, fundraising management, human resources, financial activities, asset management, financial reporting, contract management, and information disclosure [3][4]. Procurement Management - The company has established a dedicated supplier development department to manage procurement, adhering to veterinary drug production quality management standards and implementing a comprehensive procurement management system [4]. Sales Management - A complete sales system and process have been established, including credit risk management and a closed-loop management system for sales-related activities to ensure financial safety and improve capital turnover efficiency [5]. Engineering Management - The company has developed an integrated engineering management system that outlines project approval processes, responsibilities, and construction management to enhance project oversight [6]. Fundraising Management - The company has detailed regulations for the management of raised funds, ensuring proper storage, usage, and disclosure, with funds managed in designated accounts [6]. Human Resources Management - The company emphasizes sustainable development in human resources, focusing on ethical standards and professional capabilities in employee selection and training [7]. Financial Activities Management - The company has revised its fund management system to ensure strict control over monetary funds, with clear approval processes and budget management [8]. Asset Management - The company follows a physical asset management system, assigning responsibility for asset management and conducting regular checks to ensure asset safety [9]. Financial Reporting Management - The finance department prepares financial reports in accordance with relevant laws and regulations, ensuring accurate and timely reporting [9]. Contract Management - The company has established a legal review department to oversee contract management processes, ensuring compliance and risk mitigation [10]. Information Disclosure Management - The company has developed internal control systems for information disclosure to ensure the accuracy and completeness of disclosed information, enhancing communication with investors [11].
瑞普生物: 瑞普生物股份有限公司2024年度内部控制自我评价报告